Eustachian Tube DysfunctionLASt-BETNCT05998356
Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease
A study testing Balloon Eustachian Tuboplasty (BET) under general anesthesia. and Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia in people with Eustachian Tube Dysfunction, run by University Hospital, Montpellier.
Trial summary
To date, more than 130 000 Balloon Eustachian Tuboplasty (BET) procedures have been performed worldwide. This procedure is proposed in case of Obstructive Eustachian Tube Dysfunction (OETD) with or without chronic otitis media. However, the effectiveness of this procedure is still discussed amongst otolaryngologist. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Eustachian Tube Dysfunction
- What is being tested?
- Balloon Eustachian Tuboplasty (BET) under general anesthesia. and Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 96 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2023to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged between 18 and 85 years
- Clinical symptoms of OETD with Eustachian tubal score less or equal to 7/14
- Failure of well conducted medical treatment (GERD, allergy, rhinosinusitis) including pressure equalization device used for 1 month or more
- ASA score 1 or 2 (ASA : American Society of Anesthesiologists)
- Protected and vulnerable adult
- Not covered by Health insurance
- Refusal to sign informed consent form
- Subjects unable to attend all scheduled visits or to comply with all trial procedures
Who cannot join
- Palatal cleft
- Anatomical anomaly of pharyngeal Eustachian tube ostium on the treated side
- Medical history of nasopharyngeal radiotherapy
- Medical history of middle ear surgery (except myringotomy and/or tympanostomy tube)
- Eardrum perforation in the treated side
- Contraindication of general anesthesia, or major risk of general anesthesia including ASA scores of 3 and 4
Show all 9Show fewer
- Major nasal obstruction ipsilateral to the Eustachian tube to treat
- Medical history of previous Eustachian Tube Dilation
- Pregnant or nursing woman, or in childbearing age and not willing to use contraception
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease: A Multicenter Single-blinded Randomized Controlled Study
To date, more than 130 000 Balloon Eustachian Tuboplasty (BET) procedures have been performed worldwide. This procedure is proposed in case of Obstructive Eustachian Tube Dysfunction (OETD) with or without chronic otitis media. However, the effectiveness of this procedure is still discussed amongst otolaryngologist. Most of studies,were open label prospective studies comparing Eustachian tube function before and after surgical treatment. A recent meta-analysis suggests that BET procedure improves postoperative Eustachian tube function, but high-level evidence is still lacking. In this project, the investigators propose to perform the first blinded randomized controlled trial procedure to assess the changes of Eustachian tube function after BET in a population of subjects with chronic OETD with or without chronic otitis. Prognosis factors of efficacy will be also investigated during the study.
Read the detailed description
Obstructive Eustachian Tube Dysfunction (OETD) is a common medical condition whose prevalence is estimated to be 4.6% in the general population. Subjects suffering from OETD display various symptoms such as ear fullness, hearing loss, muffled hearing, pain, especially during pressure changes (airplane, diving, mountain experience…), tinnitus, ticking or popping sounds, autophony, or balance disorders. Failure to treat OETD can lead to chronic otitis media with cholesteatoma which is a severe medical condition requiring multiple surgeries and frequently associated with a permanent hearing loss and several major complications including meningitis, facial palsy and labyrinthitis. OETD medical management (pressure equalization device, in addition to medical treatment of rhinosinusitis and GERD) can be used in adults. However, high level evidence of effectiveness of such a treatment is still lacking and the success rates are unknown.
Surgical treatment such as grommets (tympanostomy tube) is only a temporary solution that might work in children, but is less effective in adults, requiring multiple surgeries during the patients lifetime for their repeated. Grommets are treating only the consequences but not the cause of OETD.
In 2010, the team of Prof. Sudhoff in Bielefeld, Germany, proposed for the first time the Balloon Dilatation of the Eustachian tube as an alternative treatment of OETD. To date, more than 75 000 Balloon Eustachian Tuboplasty (BET) procedures have been performed worldwide. However, the effectiveness of this procedure is still discussed amongst ENT physicians. Indeed, no blinded controlled randomized clinical trial was performed to address the effects of BET on Eustachian tube function. Only one randomized clinical trial using objective measures as outcomes was published so far and compared the effect of BET in addition to medical management versus medical management alone in an open label study. Knowing that the success rates of medical management are not clearly established and probably depend on the medical treatment used, the effect of the surgical procedure remains uncertain with this design of study. Another randomized controlled study used a quality-of-life questionnaire as main outcome measure 6 weeks after surgery. No objective assessment was performed as major outcome and follow-up was not sufficient for the main outcome measure. Most of published studies so far were open label prospective studies comparing Eustachian tube function before and after surgical treatment.
In this project, the investigators propose to perform the first blinded randomized controlled trial versus control procedure to assess the changes of Eustachian tube function after BET in a population of subjects with chronic OETD with or without chronic otitis, and after medical treatment failure. Prognosis factors of efficacy will be also investigated during the study. The control procedure will consist in the insertion of an Eustachian tube catheter, causing no dilation of the Eustachian tube. This procedure will allow to evaluate the effect of the balloon inflation itself on tubal function, compared to the insertion of catheter tube for probing and flushing in the Eustachian tube only. The literature reports very low rates of complication of BET surgery making this control procedure acceptable in terms of risks. The use of this type of control procedure is justified by the fact that no other reference treatment can be proposed as a reference group, and blinding the patient to the investigational arm is needed to ensure the methodological validity of the study.
Simplified study calender:
Visit 0: Selection Visit During this visit, investigators will inform patients of the study.
Visit 1: Inclusion Visit (14 days - 3 months after V0):
The subject consent will be obtained. Medical and demographic data will be collected and study examinations will be performed. Patients will be also received for an anesthesiology consultation and after randomized the in the intervention or the control group arm.
Visit 2: 2 days-3 months after V1 Intervention under general anaesthesia: ETD or control procedure.
Visit 3: 2 months (±15 days) after V2 Medical data collection and study examinations as well as ETDQ-7 questionary (Eustachian Tube Dysfunction Questionary).
Visit 4: Final Visit - 6 months (±15 days) after V2 Medical data collection and study examinations as well as ETDQ-7 questionary. End of the study for the participant.
Unscheduled visits If subject gets in contact with the site between regular visits due to acute disorders, an unscheduled visit will promptly be performed at the site. During this additional visit a physical examination, a systematic interview for recording of Adverse Event should be performed.
- Conditions
- Eustachian Tube Dysfunction
- Being tested
- Balloon Eustachian Tuboplasty (BET) under general anesthesia., Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia
- Keywords
- Eustachian tube, Balloon Eustachian Tuboplasty, Eustachian Tubal Score
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Balloon Eustachian Tuboplasty (BET) under general anesthesia.Device
Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer.
Insertion of catheter for probing and flushing the Eustachian tube under general anesthesiaDevice
Participants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group (BET procedure) | Experimental | Subjects randomly assigned to the intervention group will benefit from BET procedure Receives: Device: Balloon Eustachian Tuboplasty (BET) under general anesthesia. |
| Control group | Placebo comparator | Subjects from control group will undergo insertion of catheter for probing and flushing the Eustachian tube, the catheter won't be dilated Receives: Device: Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Eustachian Tubal Score (ETS)
The changes of Eustachian tube function will be addressed by the calculation of the difference between final (v4) and initial (v1) Eustachian Tubal Score (ETS). The ETS score is a composite score considering objective measures (tubomanometry, tympanic impedancemetry) and subjective measures (Valsalva maneuver efficacy, opening of the Eustachian tube).ETS score is highly correlated to tubal function.
Measured: ETS is calculated at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
Secondary outcomes (2)
Tympanic impedancemetry
Tympanic impedancemetry will classify ear impedancetry as normal (A) or abnormal (B or C type curves)
Measured: The measurement is performed at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
Specific Eustachian tube dysfunction score
Specific Eustachian tube dysfunction score will be assessed by the ETDQ-7 questionary that has been shown to be sensitive and specific for Eustachian tube diseases.
Measured: The ETDQ-7 questionnary is performed at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2023
- Study start1 Oct 2023 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eustachian Tube DysfunctionStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Subjects randomly assigned to the intervention (experimental) group will benefit from BET, and subjects in the control group will undergo a Eustachian tube catheter insertion for probing and flushing the Eustachian tube but without dilation.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frédéric Venail, MD, PhD, Principal investigator, University hospital of Montpellier, FRANCE
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05998356
- Sponsor's protocol ID
- RECHMPL22_0551
- Acronym
- LASt-BET
- Status last verified
- Sep 2023
- First submitted
- 7 Jun 2023
- Last updated
- 21 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease: A Multicenter Single-blinded Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT05998356
- Acronym / sponsor ID
- LASt-BET / RECHMPL22_0551
- Conditions
- Eustachian Tube Dysfunction
- Keywords
- Eustachian tube, Balloon Eustachian Tuboplasty, Eustachian Tubal Score
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- 1 Oct 2023 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 18 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To date, more than 130 000 Balloon Eustachian Tuboplasty (BET) procedures have been performed worldwide. This procedure is proposed in case of Obstructive Eustachian Tube Dysfunction (OETD) with or without chronic otitis media. However, the effectiveness of this procedure is still discussed amongst otolaryngologist. Most of studies,were open label prospective studies comparing Eustachian tube function before and after surgical treatment. A recent meta-analysis suggests that BET procedure improves postoperative Eustachian tube function, but high-level evidence is still lacking. In this project, the investigators propose to perform the first blinded randomized controlled trial procedure to assess the changes of Eustachian tube function after BET in a population of subjects with chronic OETD with or without chronic otitis. Prognosis factors of efficacy will be also investigated during the study.
Detailed description
Obstructive Eustachian Tube Dysfunction (OETD) is a common medical condition whose prevalence is estimated to be 4.6% in the general population. Subjects suffering from OETD display various symptoms such as ear fullness, hearing loss, muffled hearing, pain, especially during pressure changes (airplane, diving, mountain experience…), tinnitus, ticking or popping sounds, autophony, or balance disorders. Failure to treat OETD can lead to chronic otitis media with cholesteatoma which is a severe medical condition requiring multiple surgeries and frequently associated with a permanent hearing loss and several major complications including meningitis, facial palsy and labyrinthitis. OETD medical management (pressure equalization device, in addition to medical treatment of rhinosinusitis and GERD) can be used in adults. However, high level evidence of effectiveness of such a treatment is still lacking and the success rates are unknown.
Surgical treatment such as grommets (tympanostomy tube) is only a temporary solution that might work in children, but is less effective in adults, requiring multiple surgeries during the patients lifetime for their repeated. Grommets are treating only the consequences but not the cause of OETD.
In 2010, the team of Prof. Sudhoff in Bielefeld, Germany, proposed for the first time the Balloon Dilatation of the Eustachian tube as an alternative treatment of OETD. To date, more than 75 000 Balloon Eustachian Tuboplasty (BET) procedures have been performed worldwide. However, the effectiveness of this procedure is still discussed amongst ENT physicians. Indeed, no blinded controlled randomized clinical trial was performed to address the effects of BET on Eustachian tube function. Only one randomized clinical trial using objective measures as outcomes was published so far and compared the effect of BET in addition to medical management versus medical management alone in an open label study. Knowing that the success rates of medical management are not clearly established and probably depend on the medical treatment used, the effect of the surgical procedure remains uncertain with this design of study. Another randomized controlled study used a quality-of-life questionnaire as main outcome measure 6 weeks after surgery. No objective assessment was performed as major outcome and follow-up was not sufficient for the main outcome measure. Most of published studies so far were open label prospective studies comparing Eustachian tube function before and after surgical treatment.
In this project, the investigators propose to perform the first blinded randomized controlled trial versus control procedure to assess the changes of Eustachian tube function after BET in a population of subjects with chronic OETD with or without chronic otitis, and after medical treatment failure. Prognosis factors of efficacy will be also investigated during the study. The control procedure will consist in the insertion of an Eustachian tube catheter, causing no dilation of the Eustachian tube. This procedure will allow to evaluate the effect of the balloon inflation itself on tubal function, compared to the insertion of catheter tube for probing and flushing in the Eustachian tube only. The literature reports very low rates of complication of BET surgery making this control procedure acceptable in terms of risks. The use of this type of control procedure is justified by the fact that no other reference treatment can be proposed as a reference group, and blinding the patient to the investigational arm is needed to ensure the methodological validity of the study.
Simplified study calender:
Visit 0: Selection Visit During this visit, investigators will inform patients of the study.
Visit 1: Inclusion Visit (14 days - 3 months after V0):
The subject consent will be obtained. Medical and demographic data will be collected and study examinations will be performed. Patients will be also received for an anesthesiology consultation and after randomized the in the intervention or the control group arm.
Visit 2: 2 days-3 months after V1 Intervention under general anaesthesia: ETD or control procedure.
Visit 3: 2 months (±15 days) after V2 Medical data collection and study examinations as well as ETDQ-7 questionary (Eustachian Tube Dysfunction Questionary).
Visit 4: Final Visit - 6 months (±15 days) after V2 Medical data collection and study examinations as well as ETDQ-7 questionary. End of the study for the participant.
Unscheduled visits If subject gets in contact with the site between regular visits due to acute disorders, an unscheduled visit will promptly be performed at the site. During this additional visit a physical examination, a systematic interview for recording of Adverse Event should be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Subjects randomly assigned to the intervention (experimental) group will benefit from BET, and subjects in the control group will undergo a Eustachian tube catheter insertion for probing and flushing the Eustachian tube but without dilation.
| Arm | Type | Receives |
|---|---|---|
| Intervention group (BET procedure) | Experimental | Device: Balloon Eustachian Tuboplasty (BET) under general anesthesia.Subjects randomly assigned to the intervention group will benefit from BET procedure |
| Control group | Placebo comparator | Device: Insertion of catheter for probing and flushing the Eustachian tube under general anesthesiaSubjects from control group will undergo insertion of catheter for probing and flushing the Eustachian tube, the catheter won't be dilated |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Aged between 18 and 85 years
- Clinical symptoms of OETD with Eustachian tubal score less or equal to 7/14
- Failure of well conducted medical treatment (GERD, allergy, rhinosinusitis) including pressure equalization device used for 1 month or more
- ASA score 1 or 2 (ASA : American Society of Anesthesiologists)
- Protected and vulnerable adult
Key exclusion criteria (9 listed)
- Palatal cleft
- Anatomical anomaly of pharyngeal Eustachian tube ostium on the treated side
- Medical history of nasopharyngeal radiotherapy
- Medical history of middle ear surgery (except myringotomy and/or tympanostomy tube)
- Eardrum perforation in the treated side
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Balloon Eustachian Tuboplasty (BET) under general anesthesia.Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer. | Device | Intervention group (BET procedure) |
| Insertion of catheter for probing and flushing the Eustachian tube under general anesthesiaParticipants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study. | Device | Control group |
Primary outcome
Eustachian Tubal Score (ETS)
Time frame: ETS is calculated at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
The changes of Eustachian tube function will be addressed by the calculation of the difference between final (v4) and initial (v1) Eustachian Tubal Score (ETS). The ETS score is a composite score considering objective measures (tubomanometry, tympanic impedancemetry) and subjective measures (Valsalva maneuver efficacy, opening of the Eustachian tube).ETS score is highly correlated to tubal function.
2 secondary outcomes
Tympanic impedancemetry
Time frame: The measurement is performed at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
Specific Eustachian tube dysfunction score
Time frame: The ETDQ-7 questionnary is performed at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
Related trials for Eustachian Tube Dysfunction
Recruiting
Nasal Dilator Therapy for Patulous Eustachian Tube Dysfunction
Patulous Eustachian Tube Dysfunction, Eustachian Tube Dysfunction
Not yet recruiting
EarFlo: A Non-Invasive Treatment for Otitis Media With Effusion & Eustachian Tube Dysfunction in Adults
Otitis Media With Effusion (OME), Eustachian Tube Dysfunction
Not yet recruiting
Active vs. Passive VR During Office-based ENT Procedures
Pain, Anxiety
RecruitingObservational study
AERA Pediatrics Registry
Dysfunction of Eustachian Tube
Enrolling by invitationObservational study
Diagnostic Precision and Accuracy Using the Teed Scoring System Versus the O'Neill Grading System
Otic Barotrauma, Pressure Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frédéric Venail, MD, PhD principal investigator
University hospital of Montpellier, FRANCE
Questions about this trial
What is this clinical trial studying?
A study testing Balloon Eustachian Tuboplasty (BET) under general anesthesia. and Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia in people with Eustachian Tube Dysfunction, run by University Hospital, Montpellier.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julia Korchagina, PhD (+33 4 67 33 61 56, julia.korchagina@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Eustachian Tubal Score (ETS) (time frame: ETS is calculated at the inclusion, between 2 and 5 months after the inclusion, and between 6 and 9 months after the inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.